Menu
Recruiting NCT06161701

Steroid Diabetes in Patients With Kidney Disease

— Observational Nephrotic Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: no intervention.
Who it may be relevant to
Registry conditions: Nephrotic Syndrome. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Study on the Influencing Factors of Glucocorticoid Induced Elevated Blood Glucose in Nephrotic Patients

Overview

If steroid diabetes is not recognized in time, it will cause irreversible damage to the body. Nephropathy patients are more likely to have steroid diabetes ,the incidence rate up to 25%,due to hypoalbuminemia, high-dose hormone and other reasons, so they need to be closely followed up, identified and intervened in time.

Detailed description

1. Patients with nephrosis who had taken glucocorticoid for the first time were followed up, and those who had diabetes themselves were excluded. 2. Regularly follow up and record information on glucocorticoid medication, medications that have an impact on blood sugar, fasting blood sugar, 2-hour postprandial blood sugar, and glycated hemoglobin. 3. Notify relevant doctors of any cases of elevated blood sugar. 4. The total follow-up time is 1 year.

Interventions

  • Other no intervention
    no intervention

Primary outcome measures

  • Incidence of steroid diabetes in nephrotic patients after glucocorticoid use [Time frame: If the use of glucocorticoids exceeds one year, observe for one year; If the usage time is less than one year, observe 3 months after discontinuation of medication.]
Secondary outcome measures (1)
  • Cumulative use time of glucocorticoid, cumulative dose of glucocorticoid and drugs that may affect blood glucose in combination with steroid diabetes [Time frame: Time from enrollment to steroid diabetes happens]

Eligibility criteria

Inclusion criteria

  • Patients who need to use glucocorticoids due to the following diseases: nephrotic syndrome, Immunoglobulin A nephropathy, membranous nephropathy, Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus；
  • Initial daily dose of glucocorticoids greater than or equal to 10mg of prednisolone；

Exclusion criteria

  • Patients with diabetes；
  • Those who are unable to communicate through language；
  • Uremic patients；
  • Unable to perform blood glucose monitoring and follow-up as required；
  • Those who have used glucocorticoids within the past 3 months and have accumulated a dose of 10mg or more of prednisone；
  • Participated in other clinical studies。

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Zhejiang provincial people's hospital — Hangzhou

Identifiers

NCT: NCT06161701 · KT20220083

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗